Day 2 Program

Rapid Fire 3

Day 2: December 10, 2025

4:30 PM–5:30 PM CST

Stars at Night 1-2

Session Details

Oral presentations of high impact abstracts.
The text of the abstracts will be posted on Monday, November 24.

Moderator

Aleix Prat, Hospital Clinic Barcelona, Barcelona, Spain

RF3-01

Clinical outcomes of invasive lobular carcinoma (ILC) versus non-lobular breast cancer (NLC) assessed by expert pathologists, an artificial intelligence (AI) CDH1 classifier, and AI-derived tumor microenvironment (TME) biomarkers in TAILORx

Roberto Salgado, Peter MacCallum Cancer Centre, Melbourne, Australia

RF3-02

Gene Expression-based Subtyping of Early Triple-Negative Breast Cancer (TNBC) for Prediction of Response to Neoadjuvant Immune-chemotherapy in the NSABP B-59/GBG-96-GeparDouze Trial

Carsten Denkert, Philipps-University Marburg and University Hospital Marburg (UKGM), Marburg, Germany

RF3-03

Evaluation of a digital pathology based multimodal artificial intelligence model for prognosis and prediction of chemotherapy benefit in node-negative, hormone receptor-positive breast cancer patients: analysis of the NSABP B-20 trial.

Charles E Geyer, NSABP Foundation and UPMC Hillman Cancer Center, Pittsburgh, PA, Pittsburgh, PA

RF3-04

Tumor-informed circulating tumor DNA analysis to assess molecular residual disease for prognosis and prediction of benefit from palbociclib in the PALLAS trial

Heather A Parsons, Fred Hutchinson Cancer Center, Seattle, WA

RF3-05

Tissue-free circulating tumour DNA detection in patients with early triple negative breast cancer from the c-TRAK-TN trial

Niamh Cunningham, Royal Marsden Hospital, London, United Kingdom

RF3-06

Tumor infiltrating lymphocytes in post-NACT residual tumors in ECOG-ACRIN EA1131 – impact of intrinsic subtypes.

Sunil S Badve, Emory School of Medicine, Atlanta, GA

RF3-07

A Multimodal-Multitask Deep Learning Model Trained in NSABP B-42 and Validated in TAILORx for Late Distant Recurrence Risk in HR+ Early Breast Cancer

Eleftherios Mamounas, National Surgical Adjuvant Breast and Bowel Project and AdventHealth Cancer Institute, Orlando, FL